Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06310759 · ClinicalTrials.gov registry record

Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

A clinical trial of Urothelial Carcinoma, sponsored by Tampere University Hospital.

Recruiting
Registry status
3,000
Enrollment target
8
Study locations

NCT06310759 is a study of Urothelial Carcinoma that is actively recruiting participants, run by Tampere University Hospital. The registered enrollment target is 3,000 participants, above the 204-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (1371% higher). The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06310759, a study of Urothelial Carcinoma, is actively recruiting participants, sponsored by Tampere University Hospital.

RECRUITING
Registry status
3,000 participants
Enrollment target
8
Study locations

Study Summary

Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scope (cystoscopy). Millions of cystoscopies are performed every year worldwide for patients presenting with hematuria, but only 10% result in a cancer diagnosis. The UROSCOUT-1 trial is a prospective multicenter observational study that explores the potential of urine tumor DNA (utDNA) testing to replace a significant portion of cystoscopies in the diagnostic setting for hematuria or other reasons to rule out urothelial cancer. The goal is to enhance patient quality of life, reduce healthcare costs, and address increased workloads in urology centers. Sample collection will be conducted by mail, and the samples will be analyzed in a blinded manner, without knowledge of which patients are diagnosed with cancer. Random subsampling will be applied to cancer-negative patients to achieve an approximate 1:1 ratio between cancer-positive and -negative patients.

Conditions Studied

Urothelial Carcinoma

Study Locations (8)

Other

  • Helsinki University Hospital - Helsinki
  • Satasairaala Hospital - Pori
  • Seinäjoki Central Hospital - Seinäjoki
  • Tampere University Hospital and Tampere University - Tampere
  • Turku University Hospital - Turku
  • Kindai University Hospital - Osaka

Illinois

  • Jesse Brown Department Of Veterans Affairs Medical Center - Chicago

British Columbia

  • Vancouver Prostate Centre - Vancouver

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2024-01-08
Est. Completion 2029-12-31

Sponsor

Tampere University Hospital

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06310759

The ClinicalTrials.gov registry entry for NCT06310759 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 204-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (1371% higher). The listed sponsor is Tampere University Hospital, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT06310759 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, Illinois, British Columbia.

Frequently Asked Questions

What is clinical trial NCT06310759 about?

NCT06310759 is a clinical study titled "Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer". Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scope...

What is the current status of trial NCT06310759?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2024-01-08. Estimated completion is 2029-12-31.

What conditions does trial NCT06310759 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

Who is sponsoring clinical trial NCT06310759?

This trial is sponsored by Tampere University Hospital, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06310759 being conducted?

This trial has 8 study locations across Illinois, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urothelial Carcinoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.